Pioneer Trust Bank N A OR Has $785,000 Position in AbbVie Inc. $ABBV

Pioneer Trust Bank N A OR cut its holdings in AbbVie Inc. (NYSE:ABBV) by 10.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 4,230 shares of the company’s stock after selling 500 shares during the quarter. Pioneer Trust Bank N A OR’s holdings in AbbVie were worth $785,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Marshall & Sullivan Inc. WA acquired a new position in shares of AbbVie in the second quarter valued at approximately $25,000. TD Capital Management LLC raised its holdings in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC bought a new stake in AbbVie in the 2nd quarter valued at $28,000. Cypress Capital Management LLC WY acquired a new position in AbbVie in the 1st quarter worth $35,000. Finally, Bear Mountain Capital Inc. boosted its stake in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent research reports. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. UBS Group increased their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. HSBC set a $225.00 price target on AbbVie in a research report on Thursday, October 2nd. Finally, Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $236.57.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $225.06 on Wednesday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a 50 day moving average price of $223.67 and a 200 day moving average price of $203.22. The stock has a market capitalization of $397.76 billion, a PE ratio of 107.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 52 week low of $163.81 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.